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Abstract 
Background: The use of the dietary polyphenols as chemosensitizing agents to enhance the efficacy of conven‑
tional cytostatic drugs has recently gained the attention of scientists and clinicians as a plausible approach for over‑
coming the limitations of chemotherapy (e.g. drug resistance and cytotoxicity). The aim of this study was to investi‑
gate whether a naturally occurring diet‑based flavonoid, fisetin, at physiologically attainable concentrations, could act 
synergistically with clinically achievable doses of paclitaxel to produce growth inhibitory and/or pro‑death effects on 
A549 non‑small cell lung cancer cells, and if it does, what mechanisms might be involved.
Methods: The drug–drug interactions were analyzed based on the combination index method of Chou and Talalay 
and the data from MTT assays. To provide some insights into the mechanism underlying the synergistic action of 
fisetin and paclitaxel, selected morphological, biochemical and molecular parameters were examined, including the 
morphology of cell nuclei and mitotic spindles, the pattern of LC3‑II immunostaining, the formation of autophagic 
vacuoles at the electron and fluorescence microscopic level, the disruption of cell membrane asymmetry/integrity, 
cell cycle progression and the expression level of LC3‑II, Bax, Bcl‑2 and caspase‑3 mRNA.
Results: Here, we reported the first experimental evidence for the existence of synergism between fisetin and pacli‑
taxel in the in vitro model of non‑small cell lung cancer. This synergism was, at least partially, ascribed to the induction 
of mitotic catastrophe. The switch from the cytoprotective autophagy to the autophagic cell death was also impli‑
cated in the mechanism of the synergistic action of fisetin and paclitaxel in the A549 cells. In addition, we revealed 
that the synergism between fisetin and paclitaxel was cell line‑specific as well as that fisetin synergizes with arsenic 
trioxide, but not with mitoxantrone and methotrexate in the A549 cells.
Conclusions: Our results provide rationale for further testing of fisetin in the combination with paclitaxel or arsenic 
trioxide to obtain detailed insights into the mechanism of their synergistic action as well as to evaluate their toxicity 
towards normal cells in an animal model in vivo. We conclude that this study is potentially interesting for the develop‑
ment of novel chemotherapeutic approach to non‑small cell lung cancer.
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Background
Lung cancer is one of the most commonly diagnosed can-
cer worldwide, where it also ranks first as a leading cause 
of cancer-related deaths among both men and women 
[1]. In the clinical practice, lung carcinomas are divided 
into two main histological types: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC), where 
the other accounts for 75–85 % of total lung cancer cases 
[2]. Since a predominant number of NSCLC cases fail to 
be detected at the surgically resectable early stage of dis-
ease, therefore chemotherapy and radiotherapy remain 
the mainstay of the treatment for inoperable NSCLC 
patients. However, while there have been numerous 
drugs approved for use, they have often suffered from the 
limited clinical applicability due to the development of 
resistance by tumor cells and non-specific toxicity toward 
normal cells [3, 4]. One such a drug, paclitaxel (PTX), a 
taxane plant product derived from the bark of the pacific 
yew tree Taxus brevifolia, has demonstrated a clinically 
significant activity against a broad variety of tumor types 
and has become a first-line treatment for NSCLC [5]. 
Nevertheless, the administration of this drug at optimum 
doses and for a prolonged time has been hampered by 
the prevalence of serious side effects, such as neutrope-
nia, neuropathy, and the acquisition of clinical resistance 
as well [6]. Recently, a considerable attention has been 
given to the identification of new therapeutic agents with 
synergistic effects with paclitaxel and other conventional 
cytostatic drugs as a promising direction to overcome the 
above mentioned drug drawbacks. In general, the com-
bination therapies have proven to be more potent than 
monotherapy in the treatment of cancers. They not only 
potentiate the therapeutic efficacy of each agent alone 
and/or enable the use of reduced doses of a single drug 
but also decrease the possibility of the development of 
drug resistance [7, 8].
In this context, plant polyphenols, especially these 
from dietary sources, have recently received an increased 
scientific attention as the appropriate contenders to serve 
as a partner for traditional chemotherapeutic drugs. The 
dietary phytochemicals are commonly perceived as non-
toxic, well-tolerated, easily available, inexpensive com-
pounds that can target multiple cellular pathways [9, 10]. 
Indeed, there is evidence that these agents may potentiate 
the cytotoxic effects of chemotherapy and radiotherapy, 
protect normal cells from therapy-associated toxicity, 
increase a systemic bioavailability of cytostatic agents, 
and in some cases, even overcome chemoresistance [11, 
12]. Despite the large number of the dietary polyphenols, 
not all of them share the same anticancer activity, hence a 
considerable attention of researchers has focused on the 
selected groups, including flavonoids. In several compar-
ative studies, fisetin (3,3′,4′,7-tetrahydroxyflavone; FIS), a 
naturally occurring diet-based flavonoid, has stood alone 
as an effective anticancer agent against a broad spectrum 
of tumor cell lines, with some of the antitumor effects 
being achieved at physiologically relevant concentrations, 
and without affecting normal cells, including human 
bronchial epithelial (NHBE) cells [3, 13–18]. Therefore, 
the aim of this study was to investigate whether fisetin, at 
physiologically attainable concentrations, could act syn-
ergistically with clinically achievable doses of paclitaxel 
to produce growth inhibitory and/or pro-death effects on 
A549 non-small cell lung cancer cells, and if it does, what 
mechanisms might be involved. Here, we report the first 
experimental evidence on such synergistic action, which 
was, at least partially, ascribed to the induction of mitotic 
catastrophe and the autophagic cell death.
Materials and methods
Cell culture
The human non-small cell lung cancer cell line A549 
and the human colon adenocarcinoma cell line LoVo 
were kindly provided by Dr. P. Kopinski (Department of 
Gene Therapy, Collegium Medicum in Bydgoszcz, Nico-
laus Copernicus University, Poland) and Prof. P. Dziegiel 
(Department of Histology and Embryology, Wroclaw 
Medical University), respectively and both cell lines were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM; 
Lonza; Verviers, Belgium). The human breast adenocar-
cinoma cell line MCF-7 was purchased from American 
Type Culture Collection (ATCC; HTB-22) and main-
tained in Minimum Essential Medium (MEM, Lonza; 
Verviers, Belgium) supplemented with 1 % non-essential 
amino acids (Sigma-Aldrich; St. Louis, MO, USA). The 
human non-small cell lung cancer cell line H1299 was 
bought from American Type Culture Collection (ATCC; 
CRL-5803) and these cells were grown in Roswell Park 
Memorial 1640 medium (RPMI 1640; Sigma-Aldrich; 
St. Louis, MO, USA). All media were supplemented with 
10  % fetal bovine serum (PAA; Pasching, Austria) and 
50  µg/ml gentamycin (Sigma-Aldrich; St. Louis, MO, 
USA) and all cultures were carried out in a humidified 
atmosphere of 95 % air and 5 % CO2 at 37 °C. After reach-
ing 70–80  % confluence during the exponential growth, 
the cells were harvested with trypsin–EDTA solution 
(Sigma-Aldrich; St. Louis, MO, USA) and subcultured on 
12- or 6-well plates (at the density of 0.11 × 106 cells/well 
and 0.3 × 106 cells/well, respectively) (BD Falcon; Frank-
lin Lakes, NJ) for further experiments.
Cell treatment
Stock solutions of fisetin and paclitaxel (Sigma-Aldrich; 
St. Louis, MO, USA) at concentration of 100  mM were 
prepared in 100 % dimethyl sulfoxide (Sigma-Aldrich; St. 
Louis, MO, USA), stored at 25 °C and serially diluted in 
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complete growth medium immediately before use. After 
a 24-h incubation to allow cell attachment, paclitaxel 
(at concentrations of 0.1, 0.2, 0.3, 0.4, 0.5  µM for MTT 
assays and 0.1  µM for other experiments) or fisetin (at 
concentrations of 10, 20, 30, 40, 50 µM for MTT assays 
and 10 µM for other experiments) were added to cells for 
the indicated times as either single or combined agents at 
a fixed concentration ratio of 1:100. Preliminary screen-
ing was carried out to ascertain the incubation time and 
the treatment regimen—a sequential versus combined 
treatment (data not shown). The final concentrations of 
DMSO did not affect the cell viability (data not shown). 
Control cells were cultured under identical conditions, 
but without the addition of the tested agents.
MTT assay
The cell viability was assessed using MTT colorimetric 
assay. The cells were seeded in 12-well plates in complete 
grown medium and 24 h later, the cells were treated with 
paclitaxel at doses from 0.1 to 0.5 μM and with fisetin at 
concentrations ranging from 10 to 50  μM, either alone 
or in a fixed ratio of 1:100, for the next 24 h. The MTT 
stock solution was made by dissolving 5 mg of thiazolyl 
blue tetrazolium bromide (MTT; Sigma-Aldrich; St. 
Louis, MO, USA) in 1 mL of phosphate-buffered saline 
(PBS) and sterilized by passage through a Whatman fil-
ter (Florham Park, NJ) with a pore size of 0.2 µm. After 
the drug treatment, the cells were once washed with PBS 
and incubated for 3 h (37 °C, 5 % CO2, 95 % air atmos-
phere) in a working solution of MTT, prepared by dilut-
ing a stock solution with DMEM without phenol red 
(Lonza; Verviers, Belgium) in the ratio 1:9. The surviv-
ing cells converted MTT to formazan that generated a 
blue-purple color when dissolved in acidic isopropanol. 
Dye absorbance was measured at 570  nm using spec-
trophotometer (Spectra Academy, K-MAC, Korea). The 
experiment was repeated six times and the cell viabil-
ity was calculated as the percentage of MTT reduction, 
assuming the absorbance of control cells as 100 %. Under 
the used conditions, MTT assay allowed to estimate the 
loss in cell viability resulting from the inhibition of the 
cell proliferation, the increase in cell death or the sum of 
both processes.
Drug interaction analysis
To evaluate whether the antitumor effects of the com-
bination of fisetin and paclitaxel were synergistic, addi-
tive or antagonistic, the drug interactions were analyzed 
based on the combination index method of Chou and 
Talalay [19]. Using data obtained from MTT assays and 
CompuSyn software [20], the dose–effect curves for sin-
gle agents and their combinations were generated and the 
combination index (CI) values for each dose and the cor-
responding effect level, referred to as the fraction affected 
(fa; the fraction of cells inhibited after the drug exposure, 
e.g. 0.5 when cell growth is inhibited by 50 %), were cal-
culated. The resulting combination index offers a quanti-
tative definition for an additive effect (CI = 1), synergism 
(CI < 1), and antagonism (CI > 1) in drug combinations 
[21]. Then, to provide a visual illustration of drug inter-
actions, the Fa–CI plot was constructed by simulating CI 
values over a range of fa levels from 0.1 to 0.95.
Annexin V/propidium iodide (PI) binding assay
To assess the extent of apoptosis, the Tali Apoptosis kit—
Annexin V Alexa Fluor 488 and Propidium Iodide (Inv-
itrogen/Life Technologies, Carlsbad, CA, USA) was used 
according to the manufacturer’s instructions. In short, 
after the treatment, the cells were collected from 6-well 
plates using trypsin–EDTA solution, centrifuged at 
300×g for 8 min, resuspended in annexin binding buffer 
(ABB) and incubated with Annexin V Alexa Fluor 488 at 
room temperature (RT) in the dark for 20  min. Follow-
ing the centrifugation at 300×g for 5 min, the cells were 
again resuspended in ABB and incubated with propidium 
iodide at RT in the dark for 5  min. The cells were ana-
lyzed using Tali image-based cytometer (Invitrogen/Life 
Technologies, Carlsbad, CA, USA). The data were quan-
tified by FCS Express Research Edition software (ver-
sion 4.03; De Novo Software, New Jersey, NJ, USA) and 
expressed as the percentage of cells in each population 
(viable Annexin V−/PI−; early apoptotic Annexin V+/PI−; 
late apoptotic Annexin V+/PI+; necrotic Annexin V−/
PI+). The sum of the early and late apoptotic cells repre-
sented the total apoptosis.
Cell cycle analysis
For DNA content analysis, the Tali Cell Cycle Kit (Invit-
rogen/Life Technologies, Carlsbad, CA, USA) was used 
according to the manufacturer’s instructions. Briefly, the 
treated cells were harvested from 6-well plates by trypsi-
nization, rinsed with PBS, fixed in ice-cold 70 % ethanol 
at 4  °C, and left at −25  °C overnight. The next day, the 
cells were centrifuged at 1000×g for 5  min at 4  °C and 
washed with PBS. After the centrifugation at 500×g for 
10  min at 4  °C, the cells were resuspended in the Tali 
Cell Cycle Solution containing propidium iodide (PI), 
RNase A, and Triton X-100. Following 30-min incuba-
tion at RT in the dark, the cells were analyzed using Tali 
image-based cytometer (Invitrogen/Life Technologies, 
Carlsbad, CA, USA) and the percentage of cells in each 
phase of the cell cycle was determined using FCS Express 
Research Edition software (version 4.03; De Novo Soft-
ware, New Jersey, NJ, USA).
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Fluorescent staining of β‑tubulin and cell nuclei
For spindle morphology assessment, the cells were 
seeded on glass cover slides in 12-well plates, permitted 
to adhere overnight and then treated with fisetin and/or 
paclitaxel. After the prefixation step with 1 mM bifunc-
tional protein cross-linking reagent 3,30-dithiodipropi-
onic acid (DTSP; Sigma-Aldrich, St. Louis, MO, USA) in 
Hank’s balanced salt solution (HBSS; Sigma-Aldrich, St. 
Louis, MO, USA) for 10 min, the cells were extracted in 
TsB (0.5  % Triton X-100; Serva, Heidelberg, Germany) 
in microtubule stabilizing buffer (MTSB; 1  mM EGTA, 
4 % poly(ethylene glycol), 10 mM PIPES; Sigma-Aldrich, 
St. Louis, MO, USA) containing DTSP (dilution 1:50) 
for 10 min and rinsed with TsB for 5 min. Following the 
fixation of the cells with 4  % paraformaldehyde (Serva, 
Heidelberg, Germany) in MTSB for 15  min and three 
washing steps with PBS, the cells were incubated with 1 % 
bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, 
MO, USA) diluted in tris-buffered saline (TBS; Sigma-
Aldrich, St. Louis, MO, USA) for 15 min. β-tubulin was 
labeled using the mouse monoclonal antibody specific for 
β-tubulin (Sigma-Aldrich, St. Louis, MO, USA) diluted 
1:65 in 1  % BSA-PBS (1  h, a moist chamber). This was 
followed by rinsing the cells three times in 1 % BSA-PBS 
and incubation with the goat anti-mouse IgG-TRITC 
secondary antibody (Sigma-Aldrich, St. Louis, MO, 
USA), diluted 1:85 in PBS (45 min, a moist chamber, in 
the dark). To assess the nuclear morphology, the slides 
were incubated with 4′,6-diamino-2-phenylindole (DAPI, 
diluted 1:20,000 in distilled water; Sigma-Aldrich; St. 
Louis, MO) for 10 min in the dark. Finally, the slides were 
rinsed three times with distilled water, mounted with 
Aqua-Poly/Mount (Polysciences; Warrington, PA) and 
analyzed using Nikon Eclipse E800 fluorescence micro-
scope and NIS-Elements 4.0 software (all from Nikon; 
Tokyo, Japan). At least 100 mitotic cells from three inde-
pendent experiments were counted to determine the per-
centage of cells with the bipolar, multipolar or monopolar 
spindles.
Transmission electron microscopy
To detect the presence of autophagic vacuoles in trans-
mission electron microscope (TEM), the treated cells 
were harvested from 6-well plates, fixed with 3.6 % (v/v) 
glutaraldehyde (Polysciences; Warrington, PA) in 0.1  M 
sodium cacodylate buffer (pH 7.4; Roth; Karlsruhe, Ger-
many) for 30 min at RT and washed three times in 0.1 M 
sodium cacodylate buffer. Then, the cells were entrapped 
within fibrin clots, which were formed by the vigorous 
mixing of cell pellets with the equal volumes of the fibrin-
ogen (3 mg/ml; Sigma-Aldrich; St. Louis, MO, USA) and 
thrombin solution (50  U/ml; Biomed-Lublin; Lublin, 
Poland). Afterwards, the samples were post-fixed with 
1  % (w/v) osmium tetroxide (Serva; Heidelberg, Ger-
many) in 0.1 M sodium cacodylate buffer for 1 h at RT, 
rinsed three times with 0.1 M sodium cacodylate buffer, 
dehydrated through a graded ethanol (30–90  %; POCH 
S.A., Gliwice, Poland) and acetone (90–100  %; POCH 
S.A., Gliwice, Poland) series, infiltrated with increasing 
ratios of epoxy resin (Epon 812; Roth; Karlsruhe, Ger-
many) with hardeners (DBA and MNA; Roth; Karlsruhe, 
Germany): 100 % acetone and finally embedded in gelatin 
capsules (Ted Pella, Inc.; Redding, CA) filled with pure 
epoxy resin with DMP-30 (Roth; Karlsruhe, Germany). 
The polymerization of the resin occurred at 37  °C for 
24 h, and then at 65 °C for 120 h. The selected parts of the 
material were cut into ultra-thin sections using Reichert 
Om U3 ultramicrotome, placed on copper grids (Sigma-
Aldrich; St. Louis, MO, USA), stained with 1  % uranyl 
acetate (Ted Pella, Inc.; Redding, CA) and examined with 
JEM-100CX transmission electron microscope (JEOL; 
Tokyo, Japan).
Detection and quantification of acidic vesicular organelles 
with acridine orange staining
To detect the development of acidic vesicular organelles 
(AVOs), which are the hallmark of autophagy, the vital 
staining of A549 cells with acridine orange (AO; Sigma-
Aldrich; St. Louis, MO, USA) was performed. The cells 
were seeded on coverslips in 12-well plates and after 
the attachment, they were incubated with fisetin and/
or paclitaxel. Then, the cells were stained with medium 
containing 1 μg/ml AO for 15 min at 37 °C, washed twice 
in PBS and immediately examined with Nikon Eclipse 
E800 fluorescence microscope and NIS-Elements 4.0 
software (all from Nikon; Tokyo, Japan). The cytoplasm 
and nucleus of AO-stained cells fluoresced bright green, 
whereas the acidic autophagic vacuoles fluoresced bright 
red, as described previously [22]. To quantify the devel-
opment of AVOs, the cell pellets were stained with AO 
(1  μg/mL) for 15  min at 37  °C, washed twice with PBS 
and instantly analyzed with Tali Image-Based Cytometer 
(Invitrogen/Life Technologies, Carlsbad, CA, USA) and 
FCS Express Research Edition software (version 4.03; De 
Novo Software, New Jersey, NJ, USA). Approximately 
equal amounts of cells were measured for each sample 
and the geometric mean of red fluorescence intensity was 
used to quantify the responses. To inhibit autophagy, the 
cells were pretreated with 100  nM bafilomycin A1 (Baf 
A1) for 4  h, followed by washing with PBS and subse-
quent incubation in the absence or presence of the tested 
compounds for the indicated period of time.
Immunofluorescent staining of LC3‑II
To examine the intensity and the pattern of LC3-II 
immunostaining, the cells were seeded on glass cover 
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slides in 12-well plates and left to attach overnight. After 
the treatment with fisetin and/or paclitaxel, the cells were 
fixed with 4  % paraformaldehyde (Serva; Heidelberg, 
Germany) in PBS for 30  min, washed three times with 
PBS, permeabilized with 0.25  % Triton X-100 (Serva; 
Heidelberg, Germany) in PBS for 5  min and blocked 
with 1  % BSA (Sigma-Aldrich; St. Louis, MO, USA) in 
PBS (BSA–PBS pH 7.6) for 20 min. The staining of LC3-
II was performed using the rabbit anti-LC3-II antibody 
(Thermo Scientific; Rockford, USA) diluted 1:2000 in 
1 % BSA–PBS (1 h, RT, a moist chamber). After rinsing 
three times with 1 % BSA–PBS, the cells were incubated 
with Alexa Fluor 488-labeled goat anti-rabbit secondary 
antibody (Life Technologies Corp.; Carlsbad, CA, USA) 
diluted 1:100 in PBS (60 min, RT, a moist chamber in the 
dark). Following three washing steps with PBS, the cell 
nuclei were counterstained with DAPI (diluted 1:20,000 
in distilled water; Sigma-Aldrich; St. Louis, MO, USA) 
for 10 min. Finally, the slides were rinsed three times with 
distilled water, mounted with Aqua-Poly/Mount (Poly-
sciences; Warrington, PA) and examined using Nikon 
Eclipse E800 fluorescence microscope and NIS-Elements 
4.0 software (all from Nikon; Tokyo, Japan).
Quantitative real‑time PCR analysis
To determine the expression level of LC3-II, Bax, Bcl-2 
and caspase-3, SYBR green-based quantitative real-
time PCR was performed using LightCycler 2.0 Instru-
ment (Roche Applied Science; Mannheim, Germany) 
and LightCycler Software Version 4.0. Total RNA from 
the A549 cells was prepared by using the Total RNA kit 
(A&A biotechnology; Gdynia, Poland) according to the 
manufacturer’s protocol. The reverse transcription and 
quantitative PCR reactions were performed in a single 
20-μl LightCycler capillary (Roche Applied Science; Man-
nheim, Germany) as a one-step real-time qRT-PCR with 
TranScriba reverse transcriptase and Master Mix SYBR 
(TranScriba-qPCR Master Mix SYBR kit; A&A biotech-
nology; Gdynia, Poland) as specified by the manufac-
turer. The total reaction mixture (20 µl) contained 65 ng 
of RNA and 0.2  μM of each primer in addition to the 
TranScriba-qPCR Master Mix SYBR kit components. 
The sequences of primers were as follows: LC3-II for-
ward 5′-CGGTGATAATAGAACGATACAAGG-3′; LC3-
II reverse 5′-CTGAGATTGGTGTGGAGACG-3′; Bax 
forward 5′-AGATGTGGTCTATAATGCGTTTTCC-3′, 
Bax reverse 5′-CAGAAGGCACTAATCAAGTCAAG 
GT-3′; Bcl-2 forward 5′-AACATCGCCCTGTGGATG 
AC-3′, Bcl-2 reverse 5′-AGAGTCTTCAGAGACAGCC 
AGGAG-3′; caspase-3 forward 5′-TGGTTCATCCAG 
TCGCTTTG-3′, caspase 3 reverse 5′-CATTCTGTTGCC 
ACCTTTCG-3′. One cycle of reverse transcription was 
carried out for 10 min at 50 °C, one cycle of denaturation 
for 3 min at 95 °C, and 40 cycles of denaturation for 15 s 
at 95 °C, followed by annealing and elongation for 30 s at 
57–60  °C (depending on the primer’s melting tempera-
ture). Relative mRNA expression levels of LC3-II, cas-
pase-3, Bax, and Bcl-2 were quantified using the ΔΔCt 
method (2−ΔΔCt method) [23] and the results were nor-
malized to the expression of the housekeeping gene 
glucose 6-phosphate dehydrogenase (G6PD) or glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) and pre-
sented as a fold difference relative to a calibrator sample 
(untreated A549 cells).
Statistical analysis
Statistical analysis was performed with GraphPad Prism 
software (GraphPad Software, San Diego, CA). The non-
parametric Mann–Whitney U test was used to compare 
the differences between experimental points, and the sig-
nificance level was set to p < 0.05. Data are presented as 
mean ± standard deviation (SD).
Results
Fisetin acts synergistically with paclitaxel to decrease the 
viability of A549 cells
In the first instance, we performed MTT assays to deter-
mine the cytotoxicity of fisetin, paclitaxel and their com-
binations on the human non-small cell lung cancer A549 
cells and to evaluate whether FIS and PTX present addi-
tive, synergistic, or antagonistic effects on these cells. For 
this purpose, we chose the concentrations of fisetin (10, 
20, 30, 40, 50 μM), which are into or close to the range 
of attainable serum levels of FIS [3, 24] and the doses of 
paclitaxel (0.1, 0.2, 0.3, 0.4, 0.5 μM), which are considered 
as clinically achievable [25, 26]. Consistent with the pre-
vious reports, PTX or FIS exhibited a dose-dependent 
growth inhibitory effect on the A549 cells (Fig.  1a). It 
should be pointed that the low concentrations of fisetin 
(≤20  μM,) had a little, if any, impact on the cell viabil-
ity, allowing 95.63 % ± 5.073 (10 μM) and 88.46 % ± 7.73 
(20  μM) of the A549 cells to survive (Fig.  1a). Further-
more, PTX at concentrations up to 0.5  μM failed to 
substantially decrease the cancer cell viability, enabling 
83.55 % ± 4.84 to 72.05 % ± 5.81 of cells to remain alive 
(Fig. 1a), the results of which are in agreement with the 
earlier reports from the A549 cell line [27–30]. However, 
the combination treatments resulted in a significantly 
greater loss of the cell viability compared to the indi-
vidual agents, suggesting the synergistic growth inhibi-
tory effect of FIS and PTX on the A549 cells (Fig.  1a). 
To confirm this possibility, the interactions between FIS 
and PTX were analyzed with the median-effect principle 
of Chou and Talalay [19]. The mass-action law param-
eters, including m, Dm, and r values that represent the 
slope of the median-effect plot (shape parameter), the 
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median-effect dose (potency parameter, such as IC50, half 
maximal inhibitory concentration), and linear correlation 
coefficient of the median-effect plot (conformity param-
eter), respectively, [21] are presented in Table 1. The CI 
values at actual experimental points and different effect 
levels form 0.1 (IC10) to 0.90 (IC90) were calculated and 
shown in Tables  2 and 3, respectively. A graphical rep-
resentation of the obtained results was combination 
index curve (Fa–CI plot), in which the CI values between 
0 and 2.7 were plotted against the corresponding effect 
levels (Fig.  1b). For the actual experimental points, the 
CI values ranged from 0.15 to 0.38 at effect levels from 
0.50 (IC50) to 0.72 (IC72), indicating the strong syner-
gistic (CI < 0.3) and synergistic (0.3 ≤ CI < 0.7) interac-
tions between FIS and PTX in the doses chosen for this 
study (Table 2). Furthermore, the analysis of the CIs for 
a wide range of effect levels revealed that the interaction 
of FIS and PTX was strongly synergistic at fa values rang-
ing from 0.1 (IC10) to 0.65 (IC65) and became synergistic 
and moderately synergistic (0.7 ≤ CI < 0.85) at fa levels 
between 0.7 (IC70) and 0.85 (IC85), approaching antago-
nism at fa values above 0.95 (IC95) (Fig. 1b). Importantly, 
the maximal synergism was found when 10 μM FIS was 
combined with 0.1  μM PTX (Table  2), and since these 
concentrations represent both physiologically achievable 
level of the flavonoid and clinically relevant dose of the 
drug, therefore we selected them for further drug combi-
nation studies on mechanistic aspects, and unless other-
wise stated, the incubation time was 24 h.
In addition, it seemed relevant to determine if the 
synergistic interaction of FIS and PTX was specific to 
lung adenocarcinoma A549 cells. Thus, the effect of FIS 
and PTX applied separately or in combination was also 
assessed in other human solid tumor cell lines, including 
H1299 (large cell lung carcinoma), LoVo (colon adeno-
carcinoma) and MCF-7 (breast adenocarcinoma). As 
Fig. 1 The combined effect of fisetin (FIS) and paclitaxel (PTX) on 
the A549 cells. a The cells were treated with various concentrations 
of PTX (0.1, 0.2, 0.3, 0.4, 0.5 μM) and FIS (10, 20, 30, 40, 50 µM), either 
alone or in a fixed ratio of 1:100, for 24 h. Cell viability was determined 
by MTT colorimetric assay. Data are expressed as a percentage of the 
control. Symbols $ and # indicate statistically significant differences 
compared with FIS or PTX treatment alone, respectively (p < 0.05; 
Mann–Whitney U test). All values represent the mean ± standard 
deviation of six independent experiments. b Combination index plot 
(Fa–CI plot) for FIS and PTX co‑treatment in A549 cells. CI values are 
plotted as a function of the fractional inhibition (fa) of cell viability/
growth by computer simulation (CompuSyn software) from 0.1 to 
0.95. Triangles represent CI values derived from the actual experi‑
mental points. CI < 1 designates synergism, CI = 1 indicates additivity 
(denoted by a dashed line), and CI > 1 represents antagonism
Table 1 The mass-action law parameters for fisetin and/or 
paclitaxel in A549 cells
The data obtained from MTT assays were subjected to automated calculation 
of m, Dm (µM) and r parameters using CompuSyn software. The parameters 
m, Dm, and r are the slope, the median‑effect dose, and the linear correlation 
coefficient of the median‑effect plot, which signify the shape of the dose–effect 
curve, the potency (IC50), and the conformity of the data to the mass‑action law, 
respectively; n is the number of sets of dose–effect relationship experiments 
that were conducted
FIS fisetin, PTX paclitaxel
Compound M Dm r n
FIS 1.69 74.88 0.99 5
PTX 0.36 9.63 0.99 5
FIS + PTX 0.63 10.87 0.99 5
Table 2 The combination index values at  actual experi-
mental points for the combination of fisetin and paclitaxel
The CI values were calculated according to the method of Chou–Talalay using 
CompuSyn software. CI < 1 represents synergism, with CI of 0.1–0.3 indicating 
strong synergism, 0.3–0.7 indicating synergism, CI of 0.7–0.85 indicating 
moderate synergism, CI of 0.85–0.90 indicating slight synergism, CI of 0.90–1.10 
indicating a nearly additive effect, CI of 1.10–1.20 indicating a slight antagonism, 
and CI of 1.20–1.45 indicating a moderate antagonism
Fa fraction affected by dose, FIS fisetin, PTX paclitaxel
Drug combination CI Fa Interaction type
FIS (µM) PTX (µM)
10 0.1 0.15 0.50 Strong synergism
20 0.2 0.22 0.60 Strong synergism
30 0.3 0.28 0.66 Strong synergism
40 0.4 0.33 0.70 Synergism
50 0.5 0.38 0.72 Synergism
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shown in Fig.  2, the combination treatments produced 
the various degrees of synergism, an additive effect or 
antagonism in a cell type-specific manner. In the case 
of the LoVo cells, the Fa–CI plot showed synergism at fa 
levels ranging from 0.1 to 0.4, the moderate synergism 
and the nearly additive effect for fa values amounted to 
0.45 and 0.5, respectively, and antagonism above these 
values (Fig.  2a). The CIs for the all actual experimental 
points indicated synergism or the nearly additive effects 
(Fig. 2a, triangles). A similar but less promising interac-
tion pattern was found for the combination of FIS and 
PTX in the H1299 cells (Fig. 2b). There was a tendency 
to turn toward the additive effect and subsequently 
toward the increasing antagonism at lower values of fa 
than those observed in the case of the LoVo cell line. The 
CI values for 2 actual experimental points fell within the 
ambit of synergism and the nearly additive effect and for 
others indicated antagonism (Fig. 2b, triangles). In turn, 
the Fa–CI plot drawn up for the MCF-7 cells showed the 
strong antagonism in the whole range of effect levels 
(Fig. 2c).
It is also noteworthy that in our preliminary experi-
ments, we also tested the combinations of fisetin with 
other drugs with a potential or proven activity against 
NSCLC. The evaluation of the cytotoxicity of fisetin in 
the combination with, inter alia, mitoxantrone (MIT), 
methotrexate (MTX), and arsenic trioxide (ATO) against 
A549 cells was performed (Additional file 1: Figure S1).
Table 3 The combination index values at different effect levels for the combination of fisetin and paclitaxel
The CI values were calculated according to the method of Chou–Talalay using CompuSyn software. CI < 1 represents synergism, with a CI of 0.1–0.3 indicating strong 
synergism, 0.3–0.7 indicating synergism, and CI of 0.7–0.85 indicating moderate synergism
Fa 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
CI 0.17 0.09 0.09 0.12 0.16 0.22 0.34 0.57 1.27
Fig. 2 The combined effect of fisetin (FIS) and paclitaxel (PTX) on other solid tumor cell lines. Logarithmic combination index plot (Fa‑log(CI) plot) 
for FIS and PTX co‑treatment in a the human colon adenocarcinoma LoVo cells b the human non‑small cell lung cancer H1229 cells c the human 
breast adenocarcinoma MCF‑7 cells. CI values (logarithmic) are plotted as a function of the fractional inhibition (fa) of cell viability/growth by 
computer simulation (CompuSyn software) from 0.1 to 0.95. Triangles represent CI values derived from the actual experimental points. In the Fa‑
log(CI) plot, the synergism is indicated by a negative value (log(CI) < 0), antagonism is indicated by a positive value (log(CI) > 0), and additive effect 
(denoted by a dashed line) is indicated by 0 (log(CI) = 0)
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Collectively, our results showed that FIS synergized 
with PTX or ATO, but not MIT or MTX in A549 cells as 
well as that the synerisctic effect of FIS and PTX was cell 
line-specific.
The combination of FIS and PTX induced apoptosis 
at relatively low level but a massive appearance of the 
enlarged mononucleated and multinucleated cells
To elucidate the mechanism underlying a synergistic cyto-
toxicity between FIS and PTX in the A549 cells, the apop-
totic cell death was first measured by Annexin V/PI assay. 
As shown in Fig.  3a, the combined treatment yielded a 
higher level of Annexin V-positive cells than either agent 
alone, however even then the percentage of these cells was 
relatively low and did not exceed 11 %. Despite such a 1.5-
fold increase of the number of the apoptotic cells, when 
compared to PTX alone, their number did not reflect the 
cytotoxicity of the combination of the agents which MTT 
assay indicated on. Moreover, the expression level of cas-
pase-3 mRNA increased only twofold (2.028 ± 0.38) after 
the combined treatment, thus it correlated with a low 
fraction of the apoptotic cells (Fig. 3c). In addition, there 
were no statistically significant differences between PTX-
treated and co-treated cells (Fig.  3c). Furthermore, both 
Bax and Bcl-2 mRNAs were upregulated by PTX with or 
without FIS, but the expression of Bcl-2 remained higher 
than that of Bax (Fig.  3d, e). Therefore, the Bcl-2/Bax 
ratios were greater than 1 in the cells exposed to PTX, FIS 
or FIS/PTX and amounted to 1.23, 1.14 and 1.17, respec-
tively (Fig. 3f ). The ratio of Bcl-2 to Bax is considered to 
be more important than expression levels of individual 
proteins in determining the susceptibility of cells to apop-
tosis. The Bcl-2/Bax ratio less than 1 makes cells suscepti-
ble to apoptosis, and when this ratio is higher than 1, the 
antiapoptotic signal should prevail among the cells [31, 
32]. Similar as in the case of caspase-3, there was a lack of 
significant differences in the expression level of Bax and 
Bcl-2 between PTX-treated and co-treated cells (Fig. 3d, 
e). The quantitative analyses were further supplemented 
by the qualitative assessment of the nuclear morphology 
using fluorescence microscope and DAPI staining (Fig. 4). 
We looked for characteristic features of apoptosis, such 
as the nuclear shrinkage and fragmentation as well as the 
chromatin condensation in the A549 cells treated with FIS 
and/or PTX and we found them in both PTX-treated and 
co-treated populations, nevertheless the apoptotic cells 
did not prevail in any group, being only occasionally seen 
(Fig. 4k, l—I). Furthermore, no detectable level of apop-
tosis was seen by image-based cytometer when FIS and 
PTX were administered to the A549 cells simultaneously 
for a period of 48 or 72 h (data not shown). Instead, there 
was a marked increase in the average cell size compared to 
control cells, from 12 ± 1 µm to 14.67 ± 0.58 µm (at 48 h) 
and from 13.33 ± 1.53 µm to 16 ± 1 µm (at 72 h) (data not 
shown). All these data allow us to assume that the alter-
native cell death mechanism other than apoptosis was 
involved in the synergistic action of FIS and PTX. Indeed, 
we observed a pronounced increase of the number of the 
enlarged mononucleated and multinucleated cells in the 
cell populations incubated with paclitaxel alone and we 
ascertained that such a drug effect was potentiated by 
fisetin in a time-dependent fashion (Fig. 4g, h, k, l—II, III). 
These results prompt us to perform the cell cycle analy-
sis, since the observed morphological changes were remi-
niscent of those previously described for the mitotic cell 
death (mitotic catastrophe; MC).
The A549 cells underwent a transient G2/M arrest followed 
by polyploidy and aneuploidy, but not apoptosis after the 
simultaneous treatment with FIS and PTX
In order to determine the cell cycle effects of FIS and/
or PTX, DNA content was measured using PI staining 
and image-based cytometer at three time points: at the 
completion of the 6, 10 and 30-h incubation with the 
tested compounds. In the first time point, there was a 
significant increase in the mean percentage of cells with 
DNA content corresponding to S phase of the cell cycle 
following the single treatment with fisetin (Fig.  5c). 
Furthermore, the combination of paclitaxel and fise-
tin resulted in the accumulation of cells from G0/G1 
phase into G2/M, but the increase in G2/M arrest was 
approximately equivalent to that produced by PTX and 
FIS alone (Fig.  5b, d). This transient G2/M arrest was 
followed by two distinct events (1) the restoration of 
normal cell cycle progression during the consecutive 
hours of the incubation with FIS, since at 30  h of the 
treatment, there were no significant differences in the 
cell cycle distribution between control and FIS-treated 
cells (Fig.  5a–e); (2) the appearance of the polyploid 
cells (DNA content greater than 4 N) but also the hypo-
diploid cells (DNA content lower than 2  N) at 30  h of 
the treatment with PTX, with or without FIS (Fig. 5a, e). 
The polyploid fraction significantly increased in number 
when FIS and PTX were administered to cells simul-
taneously, in comparison to the single treatment with 
PTX (40.52 ± 5.23 vs. 17.97 ± 8.37), what clearly indi-
cated the potentiation of the effect of paclitaxel by fise-
tin (Fig. 5e). As early as 10 h of the treatment with FIS 
and PTX, the presence of the multinucleated interphase 
cells (probably tetraploid cells) that were larger than 
those seen in control cultures (Fig.  4h—II), accompa-
nied by the accumulation of cells into 4 N stage (Fig. 5d) 
was observed. After the next round of the cell cycle, the 
appearance of the polyploid cells in the DNA histogram 
analysis (Fig.  5e) as well as the giant mononucleated 
or multinucleated cells under fluorescence microscope 
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(Fig.  4l—II, III) was evident, what was consistent with 
the cell growth without the cell division. As mentioned 
above, we also noticed an increase in the mean per-
centage of cells with less than 2N DNA content, from 
3.75  ±  1.56 in control cultures to 18.83  ±  3.41 and 
22.11 ± 5.3 in PTX-only treated and co-treated popula-
tions, respectively (Fig. 5a).
In addition, to check whether the cells were able to 
recover to normal division cycles following the expo-
sure to the combination of FIS and PTX, these agents 
Fig. 3 The effect of fisetin (FIS) and/or paclitaxel (PTX) on apoptosis of A549 cells. a, b Annexin V/PI assay by image‑based cytometry. The sum of 
the early and late apoptotic cells represented the total apoptosis. a, c, d, e The A549 cells were treated with 10 µM FIS and/or 0.1 µM PTX for 24 h. b 
In another set of experiment, the cells were treated with the combination of 10 µM fisetin and 0.1 µM paclitaxel for 30 h, followed by post‑treatment 
incubation in a drug‑free medium for the next 24 or 48 h. Real‑time PCR measurement of c caspase‑3, d Bax, e Bcl‑2 mRNA expression in A549 cells. 
The expression was normalized to GAPDH and presented as a fold difference relative to a calibrator sample (untreated A549 cells; designated as 1). 
f Bcl‑2/Bax ratio. Control cells (CTRL) were cultured under identical conditions, but without the addition of the tested agents. Asterisks represent 
statistically significant differences from control cells (p < 0.05; Mann–Whitney U test). Symbols $ and # indicate statistically significant differences 
compared with FIS or PTX treatment alone, respectively (p < 0.05; Mann–Whitney U test). The data are representative of five (a, b) or three (c–e) 
independent experiments and presented as mean and standard deviation
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Fig. 4 The assessment of the nuclear morphology using DAPI staining and fluorescence microscopy. The A549 cells were incubated with 10 µM 
fisetin (FIS), 0.1 µM paclitaxel (PTX) either as single agents or in the combination for 6, 10 or 30 h. Micrographs are representative of three independ‑
ent experiments. Arrowheads indicate: (I) the shrunken or fragmented nuclei with chromatin condensation; the enlarged multinucleated (II) or 
mononucleated (III) cells. Bar 50 µm
Fig. 5 The cytometric analysis of cell cycle distribution using propidium iodide staining. The percentage of cells a with <4N DNA content, b in G0/
G1 phase, c in S phase, d in G2/M phase, and e with >4N DNA content. The A549 cells were treated with 10 µM fisetin (FIS) and/or 0.1 µM paclitaxel 
(PTX) for 6, 10 or 30 h. In another set of experiment, the cells were treated with the combination of 10 µM fisetin and 0.1 µM paclitaxel for 30 h, 
followed by post‑treatment incubation in a drug‑free medium for the next 24 or 48 h. Control cells (CTRL) were cultured under identical conditions, 
but without the addition of the tested agents. Asterisks represent statistically significant differences from control cells (p < 0.05; Mann–Whitney U 
test). Symbols $ and # indicate statistically significant differences compared with FIS or PTX treatment alone, respectively (p < 0.05; Mann–Whitney U 
test). The data are representative of five independent experiments and presented as mean and standard deviation
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were removed from the cells after 30  h of incubation 
and then they were maintained in a drug-free medium 
for the next 24 or 48  h. As shown in Fig.  5, the cells 
failed to regain normal proliferative potential in the 
time frame investigated (up to 48 h) and even most of 
them continued to accumulate in the polyploid state 
(Fig.  5e). The polyploid population at 30  h treatment 
(40.52 ± 5.23), increased to 52.87 ± 2.48 at 24 h post-
treatment, and peaked to 71.61  ±  2.87 at 48  h post-
treatment (Fig. 5e).
Since it has previously been demonstrated that the 
polyploid/aneuploid population produced as a result of 
paclitaxel exposure may undergo apoptosis in the subse-
quent cell cycles [33, 34], the post-treatment incubations 
(24 and 48 h) in a drug-free medium followed by Annexin 
V/PI assays were performed to study the final fate of the 
cells undergoing mitotic catastrophe in response to the 
combination of FIS and PTX. The results presented in 
Fig. 3b indicate that mitotic catastrophe was not followed 
by apoptosis at any time points examined.
Taken together, our results clearly demonstrated that 
FIS enhanced PTX-induced mitotic catastrophe in the 
A549 cells.
Fisetin potentiated PTX‑induced mitotic catastrophe 
through the promotion of multipolar spindle formation
To investigate cell-cycle-specific events that resulted 
in mitotic catastrophe induction under the conditions 
used in this study, the immunofluorescence staining of 
β-tubulin was performed. Since it has previously been 
shown that MC may be a consequence of the mitotic 
spindle failure, and further, since the interference with 
spindle microtubule dynamics is considered as a main 
cause of PTX-induced cytotoxicity [35], hence we asked 
whether such a drug effect would be enhanced by fise-
tin. As depicted in Fig. 6, following the 24-h exposure to 
paclitaxel, a significant part of the mitotic cells contained 
the multipolar (g—VI) or monopolar spindles (g—V) as 
well as the misaligned and missegregated chromosomes 
(h—VII), which were in clear contrast to the bipolar spin-
dles (a, d—I), the normal metaphase plates (c, f—II), the 
normal anaphase progression (c and f—III) and cytoki-
nesis (c, f—IV) seen in control and fisetin-only treated 
cells. The combination treatment markedly increased the 
incidence of the mitotic cells with the multipolar spin-
dles (Fig. 6j—VI, m) as well as the abnormal chromosome 
alignments and segregation (Fig.  6k—VII, quantitative 
data not shown) whereas the number of cells with the 
monopolar spindles (Fig. 6j—V, m) was even lower when 
compared to the single treatment with PTX. It is impor-
tant to indicate that these cells displayed either the cleav-
age failure (Fig. 6l—IX) or they underwent the multipolar 
cell division (Fig. 6j, l—VIII). The multipolar cytokinesis 
was associated with the asymmetric distribution of the 
chromatin material and resulted in several (more than 
two, usually three) aneuploid daughter cells (Fig.  6l—
VIII). Such events were hardly ever seen in control and 
fisetin-only treated cultures (Fig. 6c, f ). The presence of 
the majority of the interphase cells as the enlarged mono-
nucleated or multinucleated cells indicated that, in the 
response to the combined treatment, the cells slipped 
from mitosis without cytokinesis (Fig. 6k—X).
Altogether, our results revealed that in co-treated cell 
populations, the vast majority of the mitotic cells con-
tained the multipolar spindles that led to the cleavage 
failure or the aberrant cell division and produced the cells 
with an abnormal DNA content.
The involvement of autophagy in the synergistic action 
of fisetin with paclitaxel
Since it has earlier been demonstrated that PTX as well 
as FIS may trigger autophagy in cancer cells, there-
fore we questioned if this process may also be involved 
in the synergistic action of these compounds. In the 
first experiment, we assessed the morphology of A549 
cells at the electron microscopic level, because electron 
microscope is regarded as “a gold standard” in moni-
toring the occurrence of autophagy [36]. As shown in 
Fig. 7, the cells treated with either PTX or FIS exhibited 
the increased amount of vacuole-like structures in the 
cytoplasm area when compared to control cell popula-
tions. However, such an autophagic-like vacuolization 
appeared to be somewhat enhanced in the cells exposed 
to the combination of FIS and PTX (Fig. 7b–f). In other 
words, co-treated cells seemed to have more vacuole-like 
structures in comparison to control cells as well as PTX-
only and FIS-only treated cells. Some of these structures 
were empty and huge (Fig.  7d, e—I), whereas the other 
were filled with the amorphous materials, the membra-
nous inclusions and the organelles at the various stages 
of degradation (Fig. 7d, e, f—II). The vast majority of the 
observed vacuoles were limited by a single membrane 
(Fig.  7d, e, f—III). These changes are the hallmark fea-
tures of autolysosomes, as described previously [36]. 
The swollen mitochondria with distorted or disorgan-
ized cristae were an additional characteristic feature of 
autophagy frequently seen in the cells treated with either 
PTX or FIS (Fig.  7b, c—IV). In these cells, similar as 
observed in co-treated populations, the vast majority of 
the autophagic vacuoles were autolysosomes (Fig. 7b, c—
III). Moreover, our attention turned to the enlarged cells 
with extensive vacuolization (Fig. 7e), since it has previ-
ously been proposed that the cells undergoing mitotic 
catastrophe may die through the autophagic cell death 
[37]. This possibility was taken into account in our fur-
ther experiments (see below).
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To precisely investigate if autophagy was induced under 
the conditions used in this study, we employed acridine 
orange dye (AO) which accumulates in acidic spaces, 
such as acidic vesicular organelles (AVOs) and emits 
bright red fluorescence, the intensity of which is propor-
tional to the degree of the acidity and the volume of these 
structures [38]. AVOs are considered as the indicative of 
autophagy, therefore we assessed their presence under 
fluorescence microscope and then we quantitated the 
intensity of red fluorescence using image-based cytom-
eter at 24  h of the treatment. As depicted in Fig.  8, the 
combination of FIS and PTX promoted AVOs formation 
to a greater extent than either agent used alone. Like-
wise, there was a statistically significant increase in the 
mean intensity of red fluorescence upon the treatment of 
A549 cells with FIS and/or PTX when compared to con-
trol cultures (Fig. 8o). Of note, the highest increment in 
the red fluorescence intensity was noted when FIS and 
PTX were applied to cells simultaneously, thus statisti-
cal significance occurred also between the combined 
treatment and the treatments with either FIS or PTX 
alone (Fig.  8o). An increase in the level of red fluores-
cent signals (reflecting an increase in AVOs formation) 
was significantly reduced upon the pre-treatment of cells 
with Baf A1 (Fig. 8i, o), the late phase autophagy inhibi-
tor, which blocks the fusion of autophagosomes with 
lysosomes [39]. Furthermore, our attention was again 
turned toward the giant multinucleated cells, which were 
filled with numerous AVOs (Fig. 8g—I), therefore we also 
performed AO staining at 24 and 48  h post-treatment, 
(See figure on previous page) 
Fig. 6 Mitosis and cytokinesis abnormalities in A549 cells after treatment with fisetin (FIS) and/or paclitaxel (PTX). The A549 cells were treated with 
10 µM FIS and/or 0.1 µM PTX for 24 h or left untreated (CTRL). a–l Mitotic spindles were stained with β‑tubulin antibody in red color and DNA was 
stained by DAPI in blue color and visualized by fluorescence microscope. Arrowheads indicate: normal mitotic figures in control (a–c) and FIS‑treated 
(d–f) cells (I) bipolar spindles; (II) metaphase cells with chromosomes aligned on the metaphase plate; (III) anaphase cells; (IV) late telophase/cytoki‑
nesis; mitosis and cytokinesis defects in PTX‑treated (g–i) and co‑treated (j–l) cells (V) monopolar spindles; (VI) multipolar spindles; (VII) abnormal 
chromosome alignments and segregation; (VIII) multipolar cell division resulting from multipolar spindles; (IX) cleavage failure as a consequence of 
multipolar spindles; (X) multinucleated or mononucleated interphase cells as a morphological manifestation of mitotic slippage. Bar 50 µm. m The 
quantification of spindles abnormalities. The percentage of cells containing normal bipolar spindles (light grey columns), multipolar spindles (dark 
grey columns), and monopolar spindles (white columns) was evaluated. At least 100 cells were counted on each of the three slides. Asterisks represent 
statistically significant differences from control cells (p < 0.05; Mann–Whitney U test). Symbols $ and # indicate statistically significant differences 
compared with FIS or PTX treatment alone, respectively (p < 0.05; Mann–Whitney U test)
Fig. 7 The detection of autophagy using transmission electron microscope. The A549 cells were treated with 10 µM fisetin (FIS) and/or 0.1 µM 
paclitaxel (PTX) for 24 h or left untreated (control, CTRL). Arrowheads indicate: (I) empty autophagic‑like vacuoles; (II) autophagic‑like vacuoles filled 
with the amorphous materials, the membranous inclusions or the organelles at the various stages of degradation; (III) single‑membrane vacuoles 
(autolysosome‑like structures); (IV) the swollen mitochondria with distorted or disorganized cristae; (V) large lysosome‑like structure with electron‑
dense material. Representative micrographs of two independent experiments. Bar 2 µm
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Fig. 8 The detection of autophagy by acridine orange staining (AO). a–n Fluorescent microscope was used to visualize the acidic vesicular orga‑
nelles (AVOs; red fluorescence) as well as the cytoplasm and nucleus (green fluorescence) after the vital staining of the cells with AO, as indicated in 
Materials and methods. a–h The A549 cells were treated with 10 µM fisetin (FIS) and/or 0.1 µM paclitaxel (PTX) for 24 h or left untreated (control, 
CTRL). i, j As negative control, bafilomycin A1 (Baf A1; 100 nM) was added to the cells for a period of 4 h, followed by washing with PBS and sub‑
sequent incubation with FIS and PTX for 24 h. k–n In another set of experiment, the cells were treated with the combination of 10 µM fisetin and 
0.1 µM paclitaxel for 24 h, followed by post‑treatment incubation in a drug‑free medium for the next 24 or 48 h. Note the increased amount of AVOs 
after the treatment with FIS and/or PTX (c, e, g). Arrowheads indicate: (I) the giant multinucleated cells filled with numerous AVOs. Bar 50 µm. o The 
measurement of the red fluorescence of AO using image‑based cytometer. Asterisks represent statistically significant differences from control cells, 
and symbol ^ indicates statistically significant differences compared to the treatment with FIS plus PTX (p < 0.05; Mann–Whitney U test). Symbols $ 
and # indicate statistically significant differences compared with FIS or PTX treatment alone, respectively (p < 0.05; Mann–Whitney U test). Data are 
representative of three separate experiments and presented as mean and standard deviation
(See figure on next page) 
Fig. 9 The detection of autophagy by LC3 accumulation. a–o Fluorescent microscope was used to visualize the LC3‑II punctate staining pattern 
(green); the cell nuclei were counterstained with DAPI (blue). a–l The A549 cells were treated with 10 µM fisetin (FIS) and/or 0.1 µM paclitaxel (PTX) for 
24 h or left untreated (control, CTRL). m–o As negative control, bafilomycin A1 (Baf A1; 100 nM) was added to the cells for a period of 4 h, followed 
by washing with PBS and subsequent incubation with FIS and PTX for 24 h. Note the increase in LC3‑II puncta following FIS and PTX treatment in 
the absence or presence of Baf A1 (j, m). Bar 50 µm. p Real‑time PCR measurement of LC3‑II mRNA expression in A549 cells. The expression was 
normalized to glucose 6‑phosphate dehydrogenase (G6PD) and presented as a fold difference relative to a calibrator sample (untreated A549 cells; 
designated as 1). Error bars represent standard deviation from duplicate qRT‑PCR assays
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because at these time points we observed the most inten-
sive accumulation of polyploid cells in the response to 
FIS and PTX co-treatment. As we expected, the vast 
majority of cells were enlarged and multinucleated, and 
characterized by a massive formation of AVOs (Fig. 8k, l, 
m, n—I).
To further corroborate the occurrence of autophagy, 
the effect of tested agents on LC3 immunofluorescence 
staining pattern was investigated. Moreover, the expres-
sion level of LC3-II was assessed using real-time PCR. 
LC3 is recognized as a specific marker of autophagy 
and it exists in two forms, cytosolic LC3-I (18 kDa) and 
shorter, derived from LC3-I by proteolysis and lipid 
modification, membrane-bound form LC3-II (16  kDa), 
the level of which is directly correlated with a number 
of autophagosomes [40]. As depicted in Fig.  9a–o, the 
fluorescence staining pattern of LC3 changed from weak 
and diffuse in control cultures to a small punctate pattern 
seen in fisetin and/or paclitaxel treated cells. Moreover, 
co-treated cells (Fig. 9j) seemed to possess more LC3-II 
dots than the cells exposed to FIS (Fig. 9d) or PTX alone 
(Fig. 9g). The accumulation of LC3-II was also observed 
following Baf A1 pretreatment (Fig.  9m), the effect 
which is consistent with the inhibition of autophagy, 
as described previously [41]. Next, we examined the 
changes in mRNA expression of LC3-II and the results 
are presented in Fig. 9p. After 24 h of co-treatment, the 
cells had increased mRNA expression of LC3-II by more 
than 1.5-fold. However, in the cells exposed to FIS alone 
or PTX alone, there was only a very slight increase in the 
expression level of LC3-II compared to control cultures 
that might be attributed to the presence mainly autolys-
osomes at 24  h of treatment with FIS or PTX. Indeed, 
it has previously been shown that when mainly late 
autophagic vacuoles were accumulated in the cells, LC3-
II levels may be not different, or may differ only slightly 
from controls [42], because autophagosome-membrane-
associated protein LC3-II is degraded in the aftermath of 
the fusion of autophagosomes with lysosomes [43]. Most 
likely, this was also the case of marked, but not a dramatic 
change, in the expression of LC3-II mRNA following the 
combination treatment (Fig. 9p).
Collectively, the obtained data revealed that PTX alone 
and FIS alone induced autophagy in A549 cells, but when 
used together, these agents triggered autophagy to a 
greater extent than either agent alone.
Fisetin alone or paclitaxel alone induced the protective 
autophagy in A549 cells that switched to the autophagic 
cell death in the response to the combination of these 
agents
Autophagy has recently been proposed to play a dual role 
in cancer therapy, either as a protective mechanism which 
enables cancer cell to survive under the stressful condi-
tions or as a cancer cell death mechanism [44]. Therefore, 
we next aimed to determine the role of autophagy in the 
A549 cells treated with FIS and/or PTX. To this end, we 
pre-treated the cells with Baf A1 for 4 h and then again 
MTT assays were performed. Specifically, we were inter-
ested in whether FIS-mediated autophagy may have a 
cytoprotective or detrimental function, since the occur-
rence of autophagy in A549 has not been reported yet. As 
shown in Fig. 10a, the blockage of autophagy by Baf A1 
Fig. 10 The functional significance of autophagy in A549 cells 
treated with fisetin (FIS) and/or paclitaxel (PTX). The A549 cells were 
pre‑treated with bafilomycin A1 (Baf A1; 100 nM) for 4 h, followed 
by washing with PBS and the subsequent incubation in the absence 
or presence of 10 μM FIS and/or 0.1 μM PTX for 24 h. a Cell viability 
was determined by MTT colorimetric assay. Data are expressed as 
a percentage of the control. b The cytometric analysis of apoptosis 
using Annexin V/PI assay. The sum of the early and late apoptotic cells 
represented the total apoptosis. Asterisks represent statistically signifi‑
cant differences from control cells (p < 0.05; Mann–Whitney U test). 
Symbols & indicate statistically significant differences compared to 
the treatment with Baf A1 alone, and symbols ^ indicate statistically 
significant differences compared to the treatment with FIS alone, PTX 
alone, or FIS plus PTX (p < 0.05; Mann–Whitney U test). The data are 
representative of three independent experiments and presented as 
mean and standard deviation
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significantly decreased the cell viability in the response 
to FIS exposure from 95.63 ± 5.70 (10 μM FIS; 24 h) to 
68.56 ± 15.14 (Baf A1; 4 h, then 10 μM FIS; 24 h), sug-
gesting that FIS-induced autophagy provided a pro-
tection and a survival advantage to A549 cells against 
FIS-mediated cytotoxicity. Likewise, the interference 
with autophagy in PTX-only treated cells led to the sig-
nificant enhancement of cytotoxicity as indicated by the 
decline in the cell viability from 83.55 % ± 4.84 (0.1 μM; 
24 h) to 55.67 % ± 14.89 (Baf A1; 4 h, then 0.1 μM PTX; 
24  h) (Fig.  10a). It was an expected outcome, as pacli-
taxel has previously been shown to elicit the cytoprotec-
tive autophagy in the A549 cells [45]. In clear contrast, 
when FIS and PTX were applied simultaneously to A549 
cells, Baf A1 pre-treatment resulted in the pronounced 
increase in the cell survival from 51.32 ± 15.39 (0.1 μM 
PTX/10 μM FIS; 24 h) to 74.22 ± 11.44 (Baf A1; 4 h, then 
0.1 μM PTX/10 μM FIS; 24 h), indicating that autophagy 
was involved in the cytotoxicity of the FIS/PTX combina-
tion treatment (Fig. 10a).
It has previously been reported that the inhibition of 
a cytoprotective autophagy sensitizes cancer cells to an 
apoptotic action of chemotherapeutic agents [45], thus 
we questioned if autophagy blockage may increase the 
rate of apoptosis in FIS-treated A549 cells. As it can be 
seen in Fig. 10b, following Baf A1 exposure, the percent-
age of the Annexin V-positive cells was significantly ele-
vated from 2.24 ± 1.92 (10 μM FIS; 24 h) to 15.81 ± 0.72 
(Baf A1; 4 h, then 10 μM FIS; 24 h), indicating the pro-
tective role of autophagy against FIS-induced apoptosis. 
Furthermore, we were curious about whether such a neg-
ative interconnection between apoptosis and autophagy 
might also occur in the A549 cells exposed to the com-
bination of FIS and PTX, in which the cytotoxic mode of 
autophagy was observed. As depicted in Fig. 10b, we did 
not observe the significant increase in the percentage of 
the Annexin V-positive cells following autophagy block-
age in the A549 cells co-treated with FIS and PTX, when 
compared to the cells treated with Baf A1 alone.
Taken together, our results indicated that in A549 cells, 
FIS alone or PTX alone induced protective autophagy 
against apoptosis, however, the cytotoxic autophagy/
autophagic cell death was triggered when these agents 
were applied simultaneously to A549 cells.
Discussion
In the present paper, we reported the first experimental 
evidence for the existence of synergism between fisetin 
and paclitaxel in the in vitro model of NSCLC. This syn-
ergism was quantified by the combination index method 
of Chou and Talalay [19], which is based on the multiple 
drug effect equation derived from the median-effect prin-
ciple of the mass-action law [21]. Such preclinical drug 
combination studies in vitro and/or in animals are neces-
sary to obtain the basis and rationale for the drug combi-
nation clinical trials, since from scientific, practical and 
ethical reasons it is impossible to determine synergism in 
humans [46]. However, to avoid a lack of reproducibility 
of the in vitro tests in the clinical trials, as it is often seen 
in the clinical settings, an important issue for the in vitro 
testing of agents is the use of clinically relevant concen-
trations, on condition that the pharmacokinetic data are 
available [47]. With this in mind, our intention was to use 
the in vivo attainable concentrations of fisetin (≤20 µM) 
[3, 24] to find its synergistic combinations with clinically 
achievable doses of cytostatic drugs, such as paclitaxel, 
mitoxantrone, methotrexate or arsenic trioxide. Accord-
ing to the literature reports, the doses of PTX below or 
equal to 1 µM [25, 26], MIT below or equal to 1 µM [48], 
MTX below or equal to 1  µM [49], and ATO below or 
equal to 2  µM [50] are achievable in  vivo and clinically 
relevant. Therefore, although our studies were carried 
out in vitro, all drugs were tested at the plasma concen-
trations attainable in vivo, providing a high hope for their 
easy reproducibility into the clinical settings.
In the present studies, the CI analysis demonstrated 
that the combination effect of FIS and PTX was synergis-
tic in the A549 non-small lung cancer cells, in all concen-
trations tested and over a wide range of effect levels (fa). 
The highest degree of synergism was found when 10 μM 
FIS was combined with 0.1 μM PTX (CI = 0.15), there-
fore we selected these doses for further drug combination 
studies on mechanistic aspects. In accordance with the 
previous report of Liao et al., we have shown that 10 μM 
FIS itself was not toxic to A549 [51]. However, the con-
trary results have been obtained by Khan et al., who have 
revealed that the treatment with 10  µM fisetin for 24  h 
decreased the viability of A549 cells by 25 %, as measured 
using MTT assay [3]. Although the reasons for such a 
significant discrepancy are unclear, the differences in the 
experimental methodology, e.g. in the MTT assay and the 
cell treatment (at different degrees of confluence) may be, 
at least partially, responsible. In the case of paclitaxel, we 
noticed that 0.1 μM concentration of this drug failed to 
substantially decrease the viability of A549 cells, allowing 
~83 % of cells to remain viable, the results of which are 
in agreement with earlier reports from this cell line (for 
example, the IC50 values of PTX in A549 cells was deter-
mined to be 5 μM [27], 22.5 μM [28] or 8.20 μM [29].
Here, we also found that the combination effect of 
FIS and PTX was cell line-specific. Synergy was demon-
strated in the LoVo and H1299 cells but not in the MCF-7 
cells, where the strong antagonism was observed. In the 
LoVo and H1299 cells, the synergism was seen in a nar-
row range of effect levels, which, in the case of the lat-
ter cells may be considered as irrelevant from a clinical 
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perspective, because they represent only a minor growth 
inhibition (IC38). The genetic differences among the 
tested cell lines that contributed to the diversity in the 
obtained interaction patterns are not known for the 
moment. A simple explanation that a diverse sensitivity 
might arise from different p53 status of the used cell lines, 
has rather been dismissed, because A549 and MCF-7 cell 
lines, both having functional p53, exhibited an oppo-
site interaction pattern. However, we cannot firmly rule 
out this account since A549 (wild-type p53) and H1299 
(p53-deficient) cells, representing two histopathological 
subtypes of lung cancer, also exhibited a distinct interac-
tion pattern, and simultaneously it is possible that in the 
MCF-7 cells, the antagonistic interactions between FIS 
and PTX might be determined by other factors. Future 
studies will have to address this issue since such informa-
tion may determine the potential clinical utility of FIS/
PTX in the treatment of cancer. A cell-type dependent 
response to drugs implies the necessity to explore genes/
molecular pathways that determine the chemosensitivity 
of tested cell lines. From a clinical perspective, it means 
that careful consideration should be paid to each patient’s 
individual characteristics to choose the most beneficial 
drug combination.
To date, only several studies have evaluated the fisetin’s 
ability to potentiate the anticancer activity of classical 
chemotherapeutic agents. It has been shown that fisetin 
enhances the cytotoxicity of cisplatin, TNF and doxoru-
bicin in the H1299 non-small cell lung cancer cells [52]. 
Importantly, fisetin has also been reported to act syn-
ergistically with cisplatin in vivo, in the NT2/D1 mouse 
xenograft model [37]. In the cited study, the extent of 
tumor regression achieved with the co-treatment of fise-
tin (1 mg/kg/day) and cisplatin (1.5 mg/kg/day) was sig-
nificantly more than the monotherapeutic treatments, 
whereas no toxicity was detected. Furthermore, using 
Lewis lung carcinoma-bearing mice as an experimen-
tal model, Touil et al. have shown that when fisetin was 
combined with cyclophosphamide, a marked improve-
ment in the anticancer and antiangiogenic activity was 
observed (92 % tumor growth inhibition and a significant 
reduction in the microvessel density), with a low systemic 
toxicity [53]. However, to our knowledge, neither metho-
trexate nor mitoxantrone and arsenic trioxide have not 
been previously tested in the combination with fisetin. In 
the present study, we demonstrated that, while the com-
binations of FIS with MTX and especially with MIT do 
not deserve further attention (at least in the case of A549 
cells), its strong synergistic action with ATO on the con-
trary does.
Here, we also provided some insights into the mecha-
nism of the synergistic action of FIS and PTX in the A549 
non-small cell lung cancer cells. Firstly, we proposed that 
mitotic catastrophe, rather than apoptosis, was one of 
the possible mechanism of the synergistic cytotoxicity 
between fisetin and paclitaxel. While some of the charac-
teristic features of apoptosis were noticed, such as phos-
phatidylserine externalization, the increase in caspase-3 
mRNA level, the nuclear shrinkage and fragmentation, 
the level of these changes was relatively low and could not 
account for the extent of cell death triggered by the com-
bination of FIS and PTX. Instead, major cellular events 
associated with mitotic catastrophe, including G2/M 
arrest followed by the mitotic slippage and polyploidy/
aneuploidy, as well as the chromosome misalignment and 
missegregation and the appearance of the enlarged mon-
onucleated and multinucleated cells were predominantly 
observed in the cell populations treated with PTX alone 
and, to a greater extent, in the FIS/PTX co-treated cells. 
The polyploid/aneuploid cells were most likely the result 
of the multipolar spindle formation that led to either 
the cleavage failure or the multipolar cell division. The 
asymmetric cytokinesis following the multipolar mitosis 
resulted in the generation of three or more daughter cells 
with an abnormal DNA content, including the hypodip-
loid cells (DNA content lower than 2  N) that appeared 
in the sub-G1 peak of the DNA histogram. Indeed, it 
has previously been shown that the cells undergoing 
multipolar and asymmetric divisions may then have an 
average of 1.33N DNA instead of 2N DNA [54]. In turn, 
the cytokinesis failure was manifested morphologically as 
the enlarged mononucleated or multinucleated cells that 
probably were represented by the G2/M peak (as a con-
sequence of one round of aberrant mitosis) or the poly-
ploid fraction (that arose from another round of aberrant 
mitosis) on the DNA histograms. In fact, the G2/M peak, 
consists of both the mitotic cells (mitotic arrest) and the 
postmitotic tetraploid cells, which escape the mitotic 
block without cytokinesis [55]. Based on the fact that 
multinucleation is the hallmark of the mitotic slippage 
[55, 56], we can presume that an increased accumulation 
of G2/M phase cells at 10  h after starting of the treat-
ment with FIS plus PTX, was a result of the generation 
of postmitotic tetraploid cells (rather than mitotically 
arrested cells), since at this time point, we simultane-
ously observed a massive accumulation of the enlarged 
multinucleated cells. To determine the percentage of the 
mitotic cells, a dual-color flow cytometry analysis using 
for example PI and mitotic phosphoprotein monoclo-
nal-2 (MPM-2) or phospho-histone H3 antibody should 
be performed in the future studies. The above-mentioned 
events, all of which are related to MC, have previously 
been observed in various PTX-treated cancer cell lines 
[57, 58], including A549 cell line [59], as well as in the 
response to other microtubule-stabilizing drugs [60]. 
Although, the final outcome of mitotic catastrophe is the 
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cell death, the time in which cells die, the ultimate cause 
of the cell death as well the type of a cell death pathway 
they follow to die, may vary in depending on the genetic 
background of cells and the type of drug as well as the 
dosage and the duration of treatment [61]. At this point, 
it should be emphasized that in an international consen-
sus mitotic catastrophe is defined as an oncosuppressive 
mechanism occurring during or after a faulty mitosis 
leading to the cell death, which takes place via apoptosis 
or necrosis, rather than cell death executioner pathway 
itself [62, 63]. It has been shown that paclitaxel induces 
the activation of spindle assembly checkpoint through 
the suppression of microtubule dynamics, leading to a 
prolonged mitotic arrest before anaphase, followed by 
apoptosis [64] or eventually the mitotic exit due to either 
the checkpoint adaptation [65] or perturbation [57]. The 
resultant multinucleated G1-tetraploid cells subsequently 
arrest in postmitotic G1, as a result of the activation of a 
p53-dependent G1 checkpoint, whereas the arrest at the 
metaphase–anaphase transition and the mitotic slippage 
are most likely not mediated by p53 [66, 67]. Those cells 
either succumb directly to apoptosis (mitotic catastrophe 
followed by apoptosis) or continue another round of the 
cell cycle as a consequence of the G1 checkpoint failure. 
The latter event, leads to further polyploidization and 
aneuploidization and eventually to the cell death [57, 59]. 
Importantly, herein we demonstrated that PTX-induced 
cellular events associated with mitotic catastrophe was 
significantly potentiated by fisetin. Bearing in mind that 
A549 cells have a wild type p53 gene, one can ask why 
the post-slippage A549 cells did not arrest in the G1 post-
mitotic checkpoint, and instead entered another round 
of the cell cycle to form the polyploid progeny and how 
to account for the reported potentiation of PTX-induced 
mitotic catastrophe by fisetin. One plausible explana-
tion comes from the observation that fisetin may act as 
a strong inhibitor of the spindle checkpoint that induces 
a rapid escape from microtubule drug-induced mitotic 
arrest [68]. In the cited studies, fisetin at concentration 
of 30  µM caused a forced mitotic exit from the mitotic 
block triggered by nocodazole, taxol and monastrol in 
various human cancer cell lines, including A549 cells. 
Furthermore, there is evidence that not only p53 but also 
a prolonged spindle checkpoint-mediated mitotic arrest 
is required for the postmitotic G1 checkpoint function 
[67]. The duration of mitotic arrest has been shown to be 
critical for the stabilization and activation of p53 [55, 67]. 
Indeed, Vogel et  al. have demonstrated that in spindle 
checkpoint compromised cells, mitotic arrest is short-
ened, resulting in subsequent endoreduplication, whereas 
extending the time of mitotic block in these cells inhib-
ited endoreduplication [67]. Based on the above findings, 
we can speculate that the potentiation of PTX-induced 
mitotic catastrophe by fisetin may be associated with the 
perturbation of the spindle assembly checkpoint.
There are also several studies that reported on other 
than necrosis, non-apoptotic mechanisms leading to 
the cell death following mitotic catastrophe. In accord-
ance with our results, Kuwahara et  al. have suggested 
that the giant multinucleated cells may die through the 
autophagic cell death [69]. In our studies, mitotic catas-
trophe was not followed by apoptosis at any time points 
examined. Instead, we observed that the cells with the 
mitotic catastrophe-like phenotype were filled abun-
dantly with autolysosomes, what allows us to assume that 
these cells could be eliminated through autophagy.
The role of autophagy in cancer therapy raised a para-
dox wherein, on one hand, it can represent a protective 
mechanism that sustains tumor cell growth and sur-
vival in the face of the toxicity of the cytostatic drugs 
or radiation, but on the other hand it may constitute an 
alternative form of the programmed cell death, named 
the autophagic type II cell death [70]. In the first sce-
nario, autophagy contributes to the treatment failure, 
thus its inhibition can re-sensitize previously resistant 
cancer cells to the cytotoxic action of chemotherapy or 
radiotherapy, concurring to beneficial treatment out-
come [54]. In the latter case, autophagy may be thera-
peutically desired, as it mediates the cytotoxic effect 
of anticancer drugs, leading to tumor cell demise [71]. 
The dual role of autophagy, either as pro-survival or 
pro-death mechanism, creates the need to carefully 
examine the functional status of autophagy before the 
administration of autophagy-induced therapy. In other 
words, from a therapeutic perspective, it is extremely 
important to determine whether the increase in the 
autophagy level is a sign of responsiveness or resist-
ance to the treatment [72]. Hence, in the current stud-
ies, having established that FIS and/or PTX trigger 
autophagy in A549 cells, we then asked whether FIS 
and/or PTX-mediated autophagy may have a cytopro-
tective or detrimental function. Recent studies have 
shown that the impact of PTX on autophagy may be 
cell type-specific [73], and several reports have revealed 
that PTX-induced autophagy in the A549 cells repre-
sents a self-defense mechanism that protects these cells 
against PTX-mediated apoptosis [45]. Our observations 
were also consistent with the premise that autophagy 
induced by paclitaxel in the A549 cells is cytoprotective. 
In turn, to our knowledge, there is only one published 
study that examined the functional significance of FIS-
triggered autophagy. That study has revealed that fisetin 
promotes the autophagic cell death in the PC3 prostate 
cancer cells [74]. On the contrary, we demonstrated that 
FIS-elicited autophagy provides a survival advantage 
to the A549 cells and protects them against apoptosis 
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induced by this flavonoid. It should be emphasized that 
fisetin produced the protective autophagic response 
in the A549 cells at in  vivo achievable concentration 
(10 μM), whereas the autophagic cell death in the PC3 
cells was induced by much higher doses of fisetin (40–
120  μM) [74]. These results seem to support a more 
and more common opinion that a potential utility of 
the dietary polyphenols in anticancer therapy lies in the 
synergistic combinations rather than in monotherapy. 
Interestingly, the conversion of the autophagic func-
tion from the cytoprotective form with FIS alone or 
PTX alone to the cytotoxic form upon the exposure of 
the cells to the combination of these compounds was 
found to occur in our experimental conditions. Indeed, 
when FIS and PTX were applied simultaneously to the 
A549 cells, Baf A1 pre-treatment resulted in the resto-
ration of the cell viability to the level similar to what was 
observed with PTX treatment alone. Among the criteria 
adopted to define the cell death by autophagy, the dem-
onstration that a pharmacologic or genetic suppression 
of autophagy prevents cell death, is believed to be the 
critical one [75, 76]. This type of “autophagic switch” 
has been first demonstrated by Wilson et al., who have 
shown that autophagy can actually have dual functions 
in the same experimental system (breast tumor cells), 
acting both as a cytoprotective mechanism for radia-
tion alone and a cytotoxic mechanism when radiation 
is accompanied by vitamin D or 1.25 dihydroxy vita-
min D3 [77]. The cited authors have implicated the 
autophagic cell death in the mechanism underlying the 
radiosensitization by 1.25 dihydroxy vitamin D3. In 
another study, Gewirtz’s group have utilized vitamin D 
and its analogue in an effort to improve the effectiveness 
of radiation therapy in non-small cell lung cancer [78]. 
As in the breast tumor cell studies, the switch between 
a cytoprotective and cytostatic autophagy appeared to 
mediated the sensitization to radiation. However, the 
specific signaling pathways mediating this dual role 
of radiation-induced autophagy have not been estab-
lished so far [77, 78]. Despite the fact that we also did 
not investigate the molecular mechanism governing the 
“autophagic switch” in our experimental conditions, we 
presume that the significant intensity of the autophagy 
level in the response to the combination treatment 
could be, at least in part, a cause for such conversion. 
This assumption was based on the previous suggestions 
that a basal enhanced level of autophagy in tumor cells 
contributes to therapy resistance but a prolonged and 
excess induction may result in cell death by cellular self-
degradation [79, 80].
The concept of “molecular switches” has also been 
used in the literature to describe the crosstalk between 
apoptosis and autophagy [80]. Although the functional 
relationship between these two processes has not been 
fully clarified, it has been suggested that autophagy and 
apoptosis may occur independently of each other, coop-
erate or antagonize each other [81]. As mentioned above, 
in this paper we revealed that autophagy induced by 
FIS alone protects the A549 cells against FIS-promoted 
apoptosis. In this case, the cytoprotective function of 
autophagy was mediated through a negative modulation 
of apoptosis. However, there are also reports showing 
that the inhibition of a cytotoxic autophagy switched cell 
death to apoptosis in cancer cells [82]. Therefore, we were 
curious about whether such a cross-regulation between 
autophagy and apoptosis might also occur in the A549 
cells exposed to the combination of FIS and PTX. We did 
not observe a significant increase in the percentage of the 
apoptotic cells following autophagy blockage in the A549 
cells co-treated with FIS and PTX, thus we suppose that 
in the case of the combined treatment, the autophagic 
and apoptotic cell death are not related to each other.
Conclusions
In summary, here we demonstrate that fisetin synergizes 
with paclitaxel in A549 non-small lung cancer cell line at 
concentrations achievable in vivo. We also found that the 
possible mechanisms of this synergism involve (1) the 
induction of mitotic catastrophe probably through the pro-
motion of multipolar spindle formation (2) the elimination 
of the cells with mitotic catastrophe through autophagy 
(3) a substantial increase in the level of autophagy, which 
presumably underlies the switch from the cytoprotec-
tive autophagy (elicited by FIS alone or PTX alone) to the 
autophagic cell death. These findings seem to be relevant 
in the light of the current understanding that the manipu-
lation of autophagy in favor of the inhibition of its cyto-
protective effects and the induction of the autophagic cell 
death might be a promising approach for anticancer ther-
apy. Furthermore, since the resistance to apoptosis is the 
primary obstacle in the cancer treatment, the development 
of novel agents that elicit the non-apoptotic cell death 
pathways is now recognized as a prospective direction 
towards overcoming this limitation [17, 54]. Therefore, 
our results deserve further preclinical studies to explain in 
detail the mechanisms involved in the synergistic action of 
fisetin and paclitaxel. Simultaneously, the potential clinical 
utility of the obtained results is highly dependent on the 
evaluation of the efficacy and toxicity of the combination 
of fisetin and paclitaxel in an animal model in vivo.
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Additional file
Additional file 1: Figure S1. The combined effect of fisetin with 
mitoxantrone (MIT), or methotrexate (MTX), or arsenic trioxide (ATO). (a,b) 
Logarithmic combination index plot (Fa‑log(CI) plot) for FIS and MIT or 
MTX, respectively. CI values (logarithmic) are plotted as a function of the 
fractional inhibition (fa) of cell viability/growth by computer simulation 
(CompuSyn software) from 0.1 to 0.95. In the Fa‑log(CI) plot, the synergism 
is indicated by a negative value (log(CI) < 0), antagonism is indicated by 
a positive value (log(CI) > 0), and additive effect (denoted by a dashed 
line) is indicated by 0 (log(CI) = 0). (c) Combination index plot (Fa‑CI plot) 
for FIS and ATO co‑treatment. CI values are plotted as a function of the 
fractional inhibition (fa) of cell viability/growth by computer simulation 
(CompuSyn software) from 0.1 to 0.95. CI < 1 designates synergism, CI = 
1 indicates additivity (denoted by a dashed line), and CI > 1 represents 
antagonism. In all cases triangles represent CI values derived from the 
actual experimental points.
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